RAPT Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Net Income	-116.8	-83.84	-69.2	-52.89	-43	-36.15	-29.12
Depreciation & Amortization	3.55	2.81	1	1.12	1.33	1.24	1.38
Share-Based Compensation	17.09	11.26	9.95	8.69	2.05	1.17	0.72
Other Operating Activities	-0.89	-1	-2.77	2.59	4.14	0.79	-0.11
Operating Cash Flow	-97.05	-70.77	-61.03	-40.49	-35.47	-32.95	-27.12
Capital Expenditures	-1.13	-0.85	-0.76	-0.4	-0.84	-3.5	-1.12
Change in Investments	105.26	-44.65	-80.59	-87.04	0	0	0
Investing Cash Flow	104.13	-45.49	-81.35	-87.44	-0.84	-3.5	-1.12
Share Issuance / Repurchase	1.45	131.18	141.48	75.46	35.52	0.27	0.25
Other Financing Activities	-	-	-	-	14.38	52.47	29.86
Financing Cash Flow	1.45	131.18	141.48	75.46	49.9	52.73	30.1
Net Cash Flow	8.53	14.92	-0.89	-52.47	13.59	16.28	1.86
Free Cash Flow	-98.17	-71.62	-61.78	-40.89	-36.32	-36.45	-28.25
Free Cash Flow Margin	-	-4689.98%	-1620.27%	-810.97%	-	-	-
Free Cash Flow Per Share	-2.56	-2.20	-2.26	-1.69	-8.36	-58.58	-65.44

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).